CSL Biotherapies, a subsidiary of CSL Limited, has won a supply contract for pre-pandemic and pandemic vaccine antigens and related services to the US national stockpile from the US Department of Health and Human Services.
The contract has a maximum potential value of
$1,511,407,737.78 if all optional activities are exercised over the
duration of the contract.
Under the terms of the contract, the Government may request CSL to
manufacture and store bulk antigen that can be used against influenza
strains with pandemic potential and to develop working virus seeds for
other manufacturers and to formulate, fill and finish bulk stored
CSL Biotherapies senior vice president Dr. John Anderson said CSL
Biotherapies is committed to helping to protect the American public
against the potential impact of an influenza pandemic.
"We are proud to contribute our 45 years of successful influenza
vaccine manufacturing experience to the U.S. National Strategy for
Pandemic Influenza," Dr. Anderson added.
Funding for the CSL contract is provided by the US Department of
Health and Human Services Office of the Assistant Secretary for
Preparedness and Response, Biomedical Advanced Research and Development